Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution.
Javier GaviraJose Carlos TapiaAlejandra RomanoGeorgia AngueraMaría AguadoAida PiedraFreya BosmaSofía SánchezCristina MartinFerran AlgabaYolanda ArceTeresa Ramón Y CajalPablo M ReyPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
In our institution, 8.3% of the patients had HRD. Tumor tissue analysis failed in 18.7% of tests. ctDNA analysis is an alternative detection method. BRCA mutations are correlated with poor prognosis.